.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

A New Therapeutic Target in Non–Small Cell Lung Cancer: HER2

Dr. Iams on Emerging TKIs and ADCs in HER2-Mutant Lung Cancer

March 24th 2021

Wade T. Iams, MD, discusses the emergence of TKIs and antibody-drug conjugates in HER2-mutant lung cancer.

Dr. Bazhenova on the Importance of Testing for HER2 Mutations in Lung Cancer

March 31st 2021

Lyudmila A. Bazhenova, MD, discusses the importance of testing for HER2 mutations in lung cancer.

Dr. Porter on Potential Sequencing With ADCs and TKIs in HER2+ Lung Cancer

March 31st 2021

Jason Porter, MD, discusses potential sequencing strategies with antibody-drug conjugates and TKIs in HER2-positive lung cancer.

A New Therapeutic Target in Non–Small Cell Lung Cancer: HER2

April 23rd 2021

This article summarizes key data presented during a virtual OncLive® Scientific Interchange & Workshop in which oncologists who specialize in lung cancer treatment discussed their practices for HER2 testing and the potential role of emerging antibody-drug conjugates and novel HER2-targeted small-molecule tyrosine kinase inhibitors for treatment of HER2-altered NSCLC.